

Aggregate Data of Outlier Part D Prescribers of Opioids and Benzodiazepines

Consistent with section 6065 of the SUPPORT for Patients and Communities Act (SUPPORT Act), CMS has developed a methodology for determining outlier Part D prescribers when concurrently prescribing benzodiazepines and opioid medications. Based on this analysis, CMS sends annual letters to notify identified Part D prescribers that they are in the highest 10th percentile of Part D prescribers in their specialty and state. Individuals who take benzodiazepines and opioids together are at higher risk for adverse events and overdose. As a collaborative partner, CMS strives to provide meaningful and informative data, and believes sharing this data along with current prescribing guidelines will help Part D prescribers provide the best possible care to prevent and relieve pain and maximize function for patients with pain.

As required by section 6065 of the SUPPORT Act, CMS is making this aggregate Part D outlier prescriber information available on the CMS website. This effort is part of our data driven efforts to combat the nation's opioid crisis. Included below are aggregated outlier prescriber data by state for each Calendar Year (CY) for which the analysis was conducted to date.

Link to opioid prescribing and SUPPORT Act section 6065 methodology:
go.cms.gov/prescribing-opioids

Annual Aggregate Outlier Data by State:

State	2020 Outliers	2021 Outliers	2022 Outliers
AK	1	0	0
AL	18	12	6
AR	9	7	6
AZ	8	2	1
CA	54	32	26
CO	8	5	2
CT	4	5	1
DE	2	0	1
FL	77	44	32
GA	31	14	16
HI	2	2	0
IA	5	1	2
ID	1	2	1
IL	19	16	13
IN	15	8	14
KS	8	6	2
KY	4	9	5
LA	21	10	5
MA	5	7	6

MD	8	0	2
ME	2	1	1
MI	27	16	16
MN	2	3	2
MO	14	16	10
MS	3	2	3
MT	2	0	1
NC	25	25	15
ND	1	2	0
NE	2	3	1
NH	2	1	1
NJ	13	8	7
NM	4	2	3
NV	7	3	2
NY	31	21	10
OH	13	9	11
OK	8	6	4
OR	4	4	2
PA	26	14	16
PR	6	0	0
RI	1	2	1
SC	16	6	8
SD	1	1	1
TN	30	16	16
TX	47	35	29
UT	8	4	2
VA	13	12	4
VT	1	0	0
WA	8	6	8
WI	7	4	4
WV	4	1	2
WY	0	1	1
Total	628	406	322